| abstract |
For use by simultaneous, separate or sequential administration of 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H- Pyrido[2,3-d][3]benzoazepine-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable Salt or Hydrate and N-[5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl -2-methyl-3H-benzimidazol-5-yl)-pyrimidin-2-yl]-amine or a pharmaceutically acceptable salt thereof for the treatment of acute myeloid leukemia, chronic myeloid leukemia, breast cancer, Drugs for ovarian cancer, malignant melanoma, lung cancer, pancreatic cancer, glioblastoma, sarcoma, desmoid tumor, adenoid cystic carcinoma (ACC), colorectal cancer, prostate cancer, or medulloblastoma. |